Stephanie L. Rose, Ph.D.
Affiliations: | 2002 | University of Florida, Gainesville, Gainesville, FL, United States |
Area:
Pathology, Immunology, Microbiology BiologyGoogle:
"Stephanie Rose"Parents
Sign in to add mentor| Maureen M. Goodenow | grad student | 2002 | UF Gainesville | |
| (Human immunodeficiency virus type 1 (HIV -1) gag-pro genetic variability is related to therapy response and impacts viral fitness in specific cell types.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Ho SK, Perez EE, Rose SL, et al. (2009) Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor. Aids (London, England). 23: 1631-40 |
| Ho SK, Coman RM, Bunger JC, et al. (2008) Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response. Virology. 378: 272-81 |
| Goodenow MM, Rose SL, Tuttle DL, et al. (2003) HIV-1 fitness and macrophages. Journal of Leukocyte Biology. 74: 657-66 |
| Goodenow MM, Bloom G, Rose SL, et al. (2002) Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease. Virology. 292: 137-49 |
| Perez EE, Rose SL, Peyser B, et al. (2001) Human immunodeficiency virus type 1 protease genotype predicts immune and viral responses to combination therapy with protease inhibitors (PIs) in PI-naive patients. The Journal of Infectious Diseases. 183: 579-88 |